Patents Assigned to Assistance Publique-Hopitaux de Paris
  • Publication number: 20190351023
    Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.
    Type: Application
    Filed: March 22, 2019
    Publication date: November 21, 2019
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), Assistance Publique - Hopitaux De Paris, SORBONNE UNIVERSITE
    Inventors: David Klatzmann, David Saadoun, Patrice Cacoub, Michèle Rosenzwajg, Eliane Piaggio, Gilbert Bensimon, Claude Bernard
  • Publication number: 20190314495
    Abstract: The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.
    Type: Application
    Filed: April 25, 2019
    Publication date: October 17, 2019
    Applicants: DBV Technologies, Assistance Publique Hôpitaux De Paris, Université Paris Descartes
    Inventors: Christophe DUPONT, Pierre-Henri BENHAMOU, Bertrand DUPONT
  • Patent number: 10385401
    Abstract: An object of the invention is an in vitro method for detecting chromosomal rearrangements between at least two specific chromosomal regions in a biological sample of a human subject, which comprises the steps of: a) isolating deoxyribonucleic acid (DNA) molecules comprising said specific chromosomal regions from said biological sample, wherein said DNA molecules have an average length of X base pairs; b)amplifying the DNA molecules of step a) by a multiplex polymerase chain reaction assay, said assay comprising at least two sets of primers, wherein each set of primers is capable of hybridizing with a specific reference chromosomal region, and each set of primer comprises a plurality of primers, said primers being capable of hybridizing to a nucleic acid strand of one of the said specific chromosomal regions at sites regularly spaced of less than X/2 base pairs; and hybridizing the product of the amplification of step b) with at least one set of nucleic probes.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: August 20, 2019
    Assignee: Assistance Publique Hopitaux de Paris
    Inventors: Raphael Saffroy, Antoinette Lemoine
  • Publication number: 20190242908
    Abstract: Inventors have shown that the protein isthmin-1 (ISM-1) is expressed at kidney level in animal and human model. They have also shown that this protein is expressed on the surface but also intracellular of the circulating leukocytes. They have observed that its expression is increased when a subject suffers from INS, MCN or FSGS compared to healthy controls. Among various causes of nephrotic syndrome, ISM-1 leucocyte expression is dramatically increased in patients with INS, MCN or FSGS. Accordingly, the present invention relates to a method for diagnosing INS, MCN or FSGS in a subject comprising the steps of: i) measuring the membrane expression level of isthmin-1 on the circulating leukocytes in a biological sample obtained from said subject; ii) comparing the expression level measured at step i) with its predetermined reference value, and iii) concluding that the subject suffers from INS, MCN or FSGS when the membrane expression level of isthmin-1 is higher than its predetermined reference value.
    Type: Application
    Filed: September 7, 2017
    Publication date: August 8, 2019
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), SORBONNE UNIVERSITE
    Inventor: Jean-Jacques BOFFA
  • Patent number: 10330683
    Abstract: The emergence of mutations in tyrosine kinases following treatment of cancer patients with molecular-targeted therapy represents a major mechanism of acquired drug resistance. Here, mutations in the serpentine receptor, Smoothened (SMO) are described, which result in resistance to a Hedgehog (Hh) pathway inhibitor, such as in medulloblastoma. Amino acid substitutions in conserved residues of SMO maintain Hh signaling, but result in the inability of the Hh pathway inhibitor, GDC-0449, to bind SMO and suppress the pathway. In some embodiments, the disclosure provides for novel mutant SMO proteins and nucleic acids and for screening methods to detect SMO mutations and methods to screen for drugs that specifically modulate mutant SMO exhibiting drug resistance.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: June 25, 2019
    Assignees: Genentech, Inc., Curis, Inc., Assistance Publique-Hopitaux de Paris, Universite Paris Diderot—Paris 7
    Inventors: Frederic J. De Sauvage, Robert L. Yauch, Gerrit J. P. Dijkgraaf, Hayley Sharpe, Nicole Basset-Seguin
  • Publication number: 20190183911
    Abstract: Provided is a fast-dissolving effervescent pharmaceutical formulation of pyridoxal-5-phosphate, and to the use thereof in the treatment of neonatal epilepsy and also of metabolic disorders with a need for pyridoxal-5-phosphate.
    Type: Application
    Filed: December 18, 2018
    Publication date: June 20, 2019
    Applicant: Assistance Publique-Hopitaux De Paris
    Inventors: Stéphane Auvin, Thomas Storme, Pascal Vaconsin, Vincent Boudy
  • Patent number: 10307385
    Abstract: A gelling formulation containing ketamine or a pharmaceutically acceptable salt thereof in water, a poloxamer and one or more pharmaceutically acceptable mucoadhesive agents is provided. Also provided is a method of using the formulation for pain treatment.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: June 4, 2019
    Assignee: Assistance Publique-Hopitaux de Paris
    Inventors: Vincent Boudy, Annick Tibi, Benoît D'Hayer, Marie-Caroline Husson, Sandrine Graff De Faget
  • Publication number: 20190134006
    Abstract: The invention provides a composition for oral administration that is formulated for human administration in unit dosage form and contains as its sole active ingredient at least 100 mg biotin per unit dose.
    Type: Application
    Filed: December 31, 2018
    Publication date: May 9, 2019
    Applicant: Assistance Publique Hopitaux De Paris
    Inventors: Frédéric Sedel, Agnès BELLANGER
  • Publication number: 20190125723
    Abstract: The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention and/or the treatment of disorders associated to gammaherpesvirinae, in particular to the human herpesvirus 8 (HHV8) or the human herpes virus 4 (HHV4), and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: June 28, 2017
    Publication date: May 2, 2019
    Applicants: Assistance Publique - Hopitaux de Paris, Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Pierre et Marie Curie (Paris 6), Universite Paris Descartes, Centre National de la Recherche Scientifique (CNRS)
    Inventors: Nicolas Dupin, Anne-Geneviève Marcelin, Vincent Calvez, Philippe Grange
  • Publication number: 20190119652
    Abstract: The present invention relates to a bacteriophage strain capable of producing a lytic infection in the Escherichia coli ST131-025b:H4 clone. The burden of STl31-025b:H4 Escherichia coli clonal complex in human community and hospital-acquired infections is increasing worldwide, going along with a worrying and growing resistance to betalactams and fluoroquinolones. Bacteriophage LM33_P1 infects exclusively (100% specificity) 025b E. coli strains with 70% coverage on the two major antibiotic resistant pandemic clonal complexes STI31-025b:H4 and ST69-025b. The inventors evaluated the in vivo activity of bacteriophage LM33_P1 using three different extraintestinal virulence murine models and showed that it infects bacteria in several organs.
    Type: Application
    Filed: April 12, 2017
    Publication date: April 25, 2019
    Applicants: NSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), UNIVERSITÉ PARIS DIDEROT - PARIS 7, INSTITUT PASTEUR, UNIVERSITÉ PARIS XIII PARIS-NORD
    Inventors: Jean-Damien RICARD, Olivier CLERMONT, Laurent DEBARBIEUX, Erick DENAMUR, Nicolas DUFOUR
  • Publication number: 20190117626
    Abstract: The invention provides a composition for oral administration that is formulated for human administration in unit dosage form and contains as its sole active ingredient at least 100 mg biotin per unit dose.
    Type: Application
    Filed: December 21, 2018
    Publication date: April 25, 2019
    Applicant: Assistance Publique Hopitaux De Paris
    Inventor: Frédéric SEDEL
  • Publication number: 20190117688
    Abstract: The present invention relates to a composition comprising secreted extracellular vesicles (SEV) of cells expressing nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4(NFATC4), for use in the treatment of cancer or in the treatment or prevention of metastatic cancer. It further relates to in vitromethods for determining or predicting the therapeutic efficiency of a treatment with a composition comprising SEV of cells expressing NFATC4 in a cancer patient, based on the ability of the composition comprising SEV of cells expressing NFATC4 to induce an increase in TGF?1 expression level.
    Type: Application
    Filed: March 29, 2017
    Publication date: April 25, 2019
    Applicants: Universite Paris Diderot Paris 7, Institut National de la Sante et de la Recherche Medicale (INSERM), Assistance Publique - Hopitaux de Paris
    Inventors: Sébastien Jauliac, Livia Camargo
  • Publication number: 20190117625
    Abstract: The invention provides a composition for oral administration that is formulated for human administration in unit dosage form and contains as its sole active ingredient at least 100 mg biotin per unit dose.
    Type: Application
    Filed: December 21, 2018
    Publication date: April 25, 2019
    Applicant: Assistance Publique Hopitaux De Paris
    Inventor: Frédéric SEDEL
  • Publication number: 20190099264
    Abstract: The present invention relates to an electrospun fully biodegradable vascular valved prosthesis, allowing tissue regeneration and growth potential optionally comprising a bifurcation, preferably T-shaped, a mandrel for electrospinning said vascular valved prosthesis, and a method for electrospinning said vascular valved prosthesis.
    Type: Application
    Filed: March 21, 2017
    Publication date: April 4, 2019
    Applicants: Assistance Publique-Hôpitaux de Paris, Statice, Universite Paris Descartes
    Inventors: David Kalfa, Philippe Menasché, Pierre Pouponneau, Clément Leonard, Sébastien Perrot
  • Publication number: 20190086428
    Abstract: The present invention relates to a method of prognosis and/or diagnosis of Alzheimer's disease by determining the level and/or cellular distribution of heparan sulfates (HS) and/or heparan sulfate sulfotransferases (HSSTs) from isolating circulating immune cells in said circulating immune cells.
    Type: Application
    Filed: March 15, 2017
    Publication date: March 21, 2019
    Applicants: Universite Paris Est Creteil Val De Marne, Assistance Publique - Hopitaux de Paris
    Inventors: Dulce Papy-Garcia, Alexandre Fifre, Bruno Dubois, Sandrine Chantepie-Laborde, Mohand Ouidir Ouidja, Francis Nyasse, Patricia Albanese
  • Publication number: 20190071438
    Abstract: The invention relates to compounds of formula (I), particularly for the use thereof as a medicament, especially in the treatment or prevention of neurogenerative disorders. The invention also relates to the methods for producing said compounds, and to the pharmaceutical compositions containing same.
    Type: Application
    Filed: October 10, 2016
    Publication date: March 7, 2019
    Applicants: Institut Du Cerveau et de la Moëlle Epiniere, Centre National de la Recherche Scientifique (CNRS (CNRS), Sorbonne Universite, Assistance Publique-Hopitaux de Paris, Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris-SUD
    Inventors: Bruno Figadere, Laurent Ferrie, Gael Le Douaron, Rita Raisman-Vozari, Patrick Michel, Julia Sepulveda
  • Publication number: 20190060407
    Abstract: The invention relates to the use of interleukin-2 in treating spondyloarthritis in a human subject, wherein IL-2 is to be administered at a dose of about I to about 2 MIU/day, wherein the treatment comprises at least a first course wherein interleukin-2 is administered once per day during at least 3 consecutive days, followed by a maintenance treatment after 1 to 4 weeks.
    Type: Application
    Filed: September 9, 2016
    Publication date: February 28, 2019
    Applicants: Assistance Publique - Hôpitaux De Paris, ILTOO PHARMA, SORBONNE UNIVERSITE
    Inventors: David Klatzmann, Francis Berenbaum, Jérémie Sellam, Bruno Fautrel, Roberta Lorenzon, Patrice Cacoub
  • Patent number: 10201528
    Abstract: The invention provides methods for treating multiple sclerosis by administering biotin. The invention also provides methods for treating sequelae after multiple sclerosis attacks by administering biotin.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: February 12, 2019
    Assignee: Assistance Publique Hopitaux De Paris
    Inventor: Frédéric Sedel
  • Patent number: 10195221
    Abstract: Provided is a fast-dissolving effervescent pharmaceutical formulation of pyridoxal-5-phosphate, and to the use thereof in the treatment of neonatal epilepsy and also of metabolic disorders with a need for pyridoxal-5-phosphate.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: February 5, 2019
    Assignee: Assistance Publique-Hopitaux de Paris
    Inventors: Stéphane Auvin, Thomas Storme, Pascal Vaconsin, Vincent Boudy
  • Publication number: 20190030089
    Abstract: The invention relates to a bacterial strain of species Faecalibacterium prausnitzii deposited at the CNCM under access number CNCM I-4573, for use in the treatment and/or prevention of an inflammatory gastrointestinal illness in an individual.
    Type: Application
    Filed: January 23, 2017
    Publication date: January 31, 2019
    Applicants: Institut National De La Recherche Agronomique (INRA), Sorbonne Universite, Assistance Publique - Hopitaux de Paris
    Inventors: Philippe Langella, Rebeca Martin Rosique, Luis Bermudez Humaran, Florian Chain, Harry Sokol